---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003861"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:15:02.514053+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early

## Summary
- Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.
- Cash and short-term investments $66.5M as of Dec 31, 2023, including $7.9M from ATM and portion of data collaboration proceeds.
- Completed enrolling and implanting patients required for FDA submission in NAUTILUS pivotal trial for idiopathic generalized epilepsy more than a quarter early.
- Initial milestones achieved in first strategic data collaboration with a biotech company; expects up to $3.7M in total proceeds over nine quarters.
- Project CARE pilot to expand RNS System access to community setting on track for 1H 2024 launch; centers already implanting patients.

## SEC filing metadata
- accession: 0001193125-24-003861
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/d30824d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003861
- JSON: https://secwatch.observer/filing/0001193125-24-003861.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003861.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported preliminary financial results for the fiscal quarter and year ended December 31, 2023.
  - Period: the fiscal quarter and year ended December 31, 2023
  - Result: preliminary results
  source text: On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.